Top Markets
#1 Islamic Coin Islamic Coin +151.63%
#2 Not in Employment, Education, or Training Not in Employment, Education, or Training +18.44%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +17.99%
#4 clBTC clBTC +12.10%
#5 OpenEden OpenEden +11.81%
#6 Arowana Arowana +9.99%
#7 Akedo Akedo +9.22%
#8 Wrapped Ether (Mantle Bridge) Wrapped Ether (Mantle Bridge) +8.95%
#9 Mantle Staked Ether Mantle Staked Ether +8.55%
#10 MarsCoin MarsCoin +8.30%
Coin of the day
Islamic Coin Islamic Coin
Settings
Language
ENGLISH
Currency
USD
Theme
BioSyntech, Inc. BioSyntech, Inc.

BioSyntech, Inc.

BSYI
Rank in Stocks #40152
BioSyntech, Inc. is dedicated to developing advanced biotherapeutic thermogels... BioSyntech, Inc. is dedicated to developing advanced biotherapeutic thermogels aimed at both repairing tissues and delivering therapeutic compounds. The company's key product pipeline features BST-CarGel, a biodegradable gel designed for cartilage repair; BST-InPod, intended for alleviating heel discomfort; BST-DermOn, for managing and healing chronic wounds; BST-Ossifil, used in bone void filling; BST-Ossifix, which provides structural support for bones; and BST-Disc, focused on restoring intervertebral discs. Beyond these, BioSyntech offers injectable products leveraging BST-Gel technology to precisely deliver biotherapeutics. Its technological assets also include Arthro-BST, an arthroscopic device for the non-destructive evaluation of cartilage degradation or repair, and Mach-1, a micromechanical testing system for assessing the properties of various tissues and materials. The company also manufactures ultra-pure chitosans under the Ultrasan brand and offers both manufacturing and analytical services. Founded in 1994 and based in Laval, Canada, BioSyntech Inc. initiated administration proceedings under the Bankruptcy and Insolvency Act on May 12, 2010, and is currently undergoing reorganization.
Share Price
$0.00001
Last synced: 2025-09-24
Market Cap
$229.03K
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
CA
Trade BioSyntech, Inc. (BSYI)

Category

Healthcare
Operating Margin for BioSyntech, Inc. (BSYI)
Operating Margin as of 2026 TTM: 0.00%
According to BioSyntech, Inc. latest financial reports and stock price the company's current Operating Margin (TTM) is 0.00%. At the end of 2026 the company had an Operating Margin of 0.00%.
Operating Margin history for BioSyntech, Inc. from 2026 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
Not enough data for the provided dates.
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.97% -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
0.00% -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
31.23% -
BE
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.